Upon determination of eligibility, all patients will be randomly assigned to one of two treatment arms:~Arm A: Cisplatin, Paclitaxel and Gemcitabine~Cisplatin 75 mg/m2 IV infusion, Day 1~Paclitaxel 175 mg/m2 IV infusion, Day 1~Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8~Arm B: Cisplatin, Paclitaxel, Gemcitabine and Avastin (Bevacizumab)~Cisplatin 75 mg/m2 IV infusion, Day 1~Paclitaxel 175 mg/m2 IV infusion, Day 1~Gemcitabine 1000 mg/m2 IV infusion, Day 1 and 8~Bevacizumab 7,5 mg/m2 IV infusion, Day 1~Patients will be stratified by number of metastatic sites (one versus two or more) and the level of Lactate Dehydrogenase (normal versus high).~The regimens will be repeated every 21 days.
The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel, Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.